570 Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an IV infusion every 3 weeks to patients with advanced solid tumors
| Autor: | Fram, R.J., Garbo, L.E., Weiss, G.J., Shkolny, D., Yurkovetskiy, A.V., Bethune, C., Ramanathan, R.K., Edelman, M.J., Sausville, E.A. |
|---|---|
| Zdroj: | In EJC Supplements 2010 8(7):180-180 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect